Dr. Hicks is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1720 Nicholasville Road
Suite 701
Lexington, KY 40503Phone+1 859-276-0414Fax+1 859-276-3765
Summary
- Lee Hicks, MD is an Oncologist based in Lexington, KY, specialized in a range of conditions including branchiogenic carcinoma, anemia of blood loss, congenital sideroblastic anemia, and squamous cell carcinoma of the oropharynx and tongue. His medical education took place at the University of Louisville School of Medicine and Indiana University School of Medicine, with a subsequent fellowship in Hematology and Oncology at Ohio State University Hospital. Dr. Hicks has several medical publications under his belt and has participated in groundbreaking clinical trials including S1222 Trial and S1207 amongst others. He also received the CMS Meaningful Use Stage 1 Certification from MOSAIQ EMR, Elekta in 2013-2014.
Education & Training
Ohio State University HospitalFellowship, Hematology and Medical Oncology, 1991 - 1994
Indiana University School of MedicineResidency, Internal Medicine, 1988 - 1991
University of Louisville School of MedicineClass of 1988
Certifications & Licensure
KY State Medical License 1994 - 2025
OH State Medical License 1991 - 1994- American Board of Internal Medicine Medical Oncology
- National Board of Physicians and Surgeons Internal Medicine
- National Board of Physicians and Surgeons Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification MOSAIQ EMR, Elekta, 2013-2014
Clinical Trials
- Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting Start of enrollment: 2010 Dec 02
- Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
- S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer Start of enrollment: 2013 Sep 12
- Join now to see all
Publications & Presentations
PubMed
- Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patients WithWild-Type, HER2-Positive, Metastatic Colorectal Cancer (S1613): A Randomized Phase II Trial.Kanwal Pratap Singh Raghav, Katherine A Guthrie, Benjamin Tan Jr, Crystal S Denlinger, Marwan Fakih
Journal of Clinical Oncology. 2025-01-06 - 4 citationsA multicenter phase 1/2 study investigating the safety, pharmacokinetics, pharmacodynamics and efficacy of a small molecule antimetabolite, RX-3117, plus nab-paclitaxe...Hani M. Babiker, Peter J. Schlegel, Lee G. Hicks, Andrea J. Bullock, Nafisa Burhani
Investigational New Drugs. 2021-08-21 - 13 citationsA phase II study of chloroquinoxaline sulfonamide (CQS) in patients with metastatic colorectal carcinoma (MCRC).Tanios Bekaii-Saab, Amir Mortazavi, Lee G. Hicks, Mark M. Zalupski, Robert Pelley
Investigational New Drugs. 2006-01-28
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
